Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Multi-trace elements injection III is a sterile, concentrated solution of essential trace elements developed by Fresenius Kabi for intravenous administration. It is primarily indicated as a supplement to parenteral nutrition in adult patients to prevent or treat trace element deficiencies. The formulation typically contains nine essential elements: iron, zinc, manganese, copper, chromium, selenium, molybdenum, iodine, and fluorine. These elements serve as critical cofactors for a wide array of metabolic enzymes, contribute to the structural integrity of proteins like hemoglobin, and participate in antioxidant defense mechanisms. By providing these micronutrients directly into the systemic circulation, the injection ensures the maintenance of physiological functions in patients with impaired gastrointestinal absorption or those requiring long-term nutritional support.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on multi-trace elements injection III.